EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma

Peizhe Yuan, Yu Long, Nannan Wei, Yan Wang, Ziyang Zhu, Jinquan Han, Dawei Jiang, Xiaoli Lan, Yongkang Gai iD

Journal for ImmunoTherapy of Cancer · 2024

DOI: 10.1136/jitc-2024-009010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2024. Verfasst von Peizhe Yuan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Positron-Emission Tomography, Immunotherapy, Lymphocyte Activation Gene 3 Protein. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Hubei Provincial Natural Science Foundation, Key Research and Development Program of Hubei Province, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Lymphocyte activation gene 3 (LAG-3) is expressed on activated immune cells and has emerged as a promising target for immune checkpoints blockade. However, conflicting findings have been reported regarding the association between LAG-3 expression in tumors and patient prognosis, indicating the need for further investigation into the significance of LAG-3 expression levels in tumor therapies. In this study, 68 Ga-NOTA-XH05, a novel peptide-based positron emission tomography (PET) tracer targeting LAG-3, was constructed to non-invasively detect LAG-3 expression in melanoma after CpG oligonucleotide (CpG) treatment and explore the relationship between LAG-3 expression and therapeutic effect.

Methods

The tracer 68 Ga-NOTA-XH05 was identified by high-performance liquid chromatography after being prepared and purified. Cell uptake and blocking essays were performed to verify the specificity of the tracer in vitro. The expression of LAG-3 in B16-F10 subcutaneous tumors was monitored by flow cytometry, and its correlation with the tracer uptake was analyzed to evaluate the tracer specificity. PET imaging and biodistribution studies were conducted after CpG treatment of unilateral or bilateral B16-F10 subcutaneous tumor models to assess the ability of 68 Ga-NOTA-XH05 in monitoring immunotherapy efficacy and the abscopal effect of CpG.

Results

Following purification, 68 Ga-NOTA-XH05 exhibited high radiochemical purity and specificity. Flow cytometry analysis revealed a positive correlation between LAG-3 expression in tumors and the uptake of 68 Ga-NOTA-XH05. In B16-F10 bearing mice treated with CpG, PET imaging using 68 Ga-NOTA-XH05 demonstrated a higher tumor to blood ratio (TBR) compared with the control group. Furthermore, TBR values obtained from CpG-treated mice allowed for differentiation between responders and non-responders. In a bilateral subcutaneous tumor model where only right-sided tumors were treated with intratumoral injection of CpG, TBR values of left-sided tumors were significantly higher than those in the control group, indicating that 68 Ga-NOTA-XH05 could effectively monitor the systemic effect of local CpG injection.

Conclusion

Our findings highlight the detection capability of 68 Ga-NOTA-XH05 in assessing LAG-3 expression levels within tumors and evaluating response to immunotherapy, thereby suggesting promising clinical translational prospects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Positron-Emission TomographyImmunotherapyLymphocyte Activation Gene 3 ProteinAnimalsMiceHumansAntigens, CDCell Line, TumorMelanoma, ExperimentalPeptidesGallium RadioisotopesMelanomaFemaleRadiopharmaceuticals

Stichwörter der Autor:innen

PET

Substanzen

Lymphocyte Activation Gene 3 ProteinAntigens, CDPeptidesGallium RadioisotopesRadiopharmaceuticals

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Hubei Province Key Laboratory of Molecular Imaging, Wuhan, China.
  • Key Laboratory of Biological Targeted Therapy, the Ministry of Education, Wuhan, People's Republic of China.
  • Department of Oncology, Liyuan Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Wuhan-Britain China School, Wuhan, China.
  • Department of Nuclear Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China gykmail@hust.edu.cn xiaoli_lan@hust.edu.cn.

ORCID-Profile: Yongkang Gai

Förderung

  • Hubei Provincial Natural Science Foundation
  • Key Research and Development Program of Hubei Province
  • National Natural Science Foundation of China

Zitieren

APA

Yuan, P., Long, Y., Wei, N., Wang, Y., Zhu, Z., Han, J., Jiang, D., Lan, X., & Gai, Y. (2024). Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2024-009010

Vancouver

Yuan P, Long Y, Wei N, Wang Y, Zhu Z, Han J, et al. Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma. Journal for ImmunoTherapy of Cancer. 2024. doi:10.1136/jitc-2024-009010

BibTeX
@article{Yuan2024,
  author = {Yuan, Peizhe and Long, Yu and Wei, Nannan and Wang, Yan and Zhu, Ziyang and Han, Jinquan and Jiang, Dawei and Lan, Xiaoli and Gai, Yongkang},
  title = {Peptide-based PET tracer targeting LAG-3 for evaluating the efficacy of immunotherapy in melanoma},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2024},
  doi = {10.1136/jitc-2024-009010}
}
Kostenlos starten →